Live, Attenuated Salmonella Vaccine Vectors

作者: Sims K. Kochi , Kevin P. Killeen

DOI: 10.1007/978-1-4615-0053-7_4

关键词:

摘要: There were few effective means available for preventing human infectious diseases prior to the beginning of 19th century, and millions people succumbed smallpox, cholera, diphtheria, typhoid fever, influenza. In late 1700s, Edward Jenner conceived notion vaccinate humans with a naturally attenuated virus protect against smallpox infection. More than century later, Louis Pasteur established basis modern live, vaccine technology by intentionally attenuating microorganism using it infection 1. The number vaccines in 21st industrialized countries has increased considerably since times (Fig. 1). ease which travel today from one country another an estimated 2.5 billion travelers per year. Virtually any place world can be reached within 36 hours, less incubation period most diseases. Thirty million alone trek regions every year where Hepatitis A is endemic, many others face potential exposure diarrhea-causing bacteria, yellow malaria. Vaccines these are inadequate or do not exist. also continues pressing need similar types developing particularly those ravaged natural disaster civil war. These needs accentuated increasing polarization between standards living rich poor nations make issues cost availability plainly evident.

参考文章(93)
Maurice Hofnung, Chapter 4 Expression of Foreign Polypeptides at the Escherichia coli Cell Surface Methods in Cell Biology. ,vol. 34, pp. 77- 105 ,(1991) , 10.1016/S0091-679X(08)61677-5
P Berche, P J Sansonetti, J L Gaillard, Intracellular growth of Listeria monocytogenes as a prerequisite for in vivo induction of T cell-mediated immunity. Journal of Immunology. ,vol. 138, pp. 2266- 2271 ,(1987)
M F Edwards, B A Stocker, Construction of delta aroA his delta pur strains of Salmonella typhi. Journal of Bacteriology. ,vol. 170, pp. 3991- 3995 ,(1988) , 10.1128/JB.170.9.3991-3995.1988
Matthew L. Albert, Birthe Sauter, Nina Bhardwaj, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature. ,vol. 392, pp. 86- 89 ,(1998) , 10.1038/32183
Holger Rüssmann, Emeka I. Igwe, Jeannette Sauer, Wolf-Dietrich Hardt, Andreas Bubert, Gernot Geginat, Protection Against Murine Listeriosis by Oral Vaccination with Recombinant Salmonella Expressing Hybrid Yersinia Type III Proteins Journal of Immunology. ,vol. 167, pp. 357- 365 ,(2001) , 10.4049/JIMMUNOL.167.1.357
K. Brooks Low, Martina Ittensohn, Trung Le, James Platt, Stefano Sodi, Max Amoss, Olivia Ash, Ellen Carmichael, Ashok Chakraborty, Jessica Fischer, Stanley L. Lin, Xiang Luo, Samuel I. Miller, Li-mou Zheng, Ivan King, John M. Pawelek, David Bermudes*, Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo Nature Biotechnology. ,vol. 17, pp. 37- 41 ,(1999) , 10.1038/5205
Warren J. Simpson, Rex E. Thomas, Tom G. Schwan, Recombinant capsular antigen (Fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. American Journal of Tropical Medicine and Hygiene. ,vol. 43, pp. 389- 396 ,(1990) , 10.4269/AJTMH.1990.43.389
Lorraine Arntzen, Margaretha Isaäcson, Guy L. Tyndal, James E. Williams, Application of enzyme immunoassays for the confirmation of clinically suspect plague in Namibia, 1982 Bulletin of The World Health Organization. ,vol. 64, pp. 745- 752 ,(1986)
C O Tacket, B Forrest, R Morona, S R Attridge, J LaBrooy, B D Tall, M Reymann, D Rowley, M M Levine, Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infection and Immunity. ,vol. 58, pp. 1620- 1627 ,(1990) , 10.1128/IAI.58.6.1620-1627.1990